

# rivaroxaban (XARELTO) Anticoagulation or Thromboprophylaxis [4163]

Use caution in patients with acute renal failure.

## Medications

### rivaroxaban (XARELTO) Thromboprophylaxis or Anticoagulation (Single Response) (Selection Required)

( ) Non-valvular atrial fibrillation (to prevent stroke and systemic embolism)

Pharmacy consult to monitor rivaroxaban (XARELTO) therapy STAT, Until discontinued, Starting S  
Indications: Atrial Fibrillation

rivaroxaban (XARELTO) (Single Response)  
Renal dose reduction recommended in patients with a CrCl LESS than 50mL/min

( ) Normal dosing 20 mg, oral, daily at 1700  
Indications: Atrial Fibrillation

( ) Renal dose reduction 15 mg, oral, daily at 1700  
Indications: Atrial Fibrillation

( ) Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)

Pharmacy consult to monitor rivaroxaban (XARELTO) therapy STAT, Until discontinued, Starting S  
Indications: Deep vein thrombosis / Pulmonary embolism

rivaroxaban (XARELTO) for DVT or PE (Single Response)  
Avoid use in patients with CrCl LESS than 30mL/min

( ) Initial treatment **"Followed by" Linked Panel**

rivaroxaban (XARELTO) tablet 15 mg, oral, 2 times daily at 0900, 1700  
Indications: Deep vein thrombosis / Pulmonary embolism

rivaroxaban (XARELTO) tablet 20 mg, oral, daily at 1700  
Indications: Deep vein thrombosis / Pulmonary embolism

( ) Continuation of treatment therapy

rivaroxaban (XARELTO) tablet 20 mg, oral, daily at 1700  
Indications: Deep vein thrombosis / Pulmonary embolism

( ) Prevention of recurrent DVT or PE following treatment doses for at least 6 months

Avoid use in patients with CrCl LESS than 30 mL/min

Pharmacy consult to monitor rivaroxaban (XARELTO) therapy STAT, Until discontinued, Starting S  
Indications: Prevention of recurrent DVT or PE

rivaroxaban (XARELTO)  
 rivaroxaban (XARELTO) tablet 10 mg, oral, daily at 1700  
Indications: Prevention of recurrent DVT or PE

( ) Risk reduction in coronary artery disease or peripheral artery disease

Pharmacy consult to monitor rivaroxaban (XARELTO) therapy STAT, Until discontinued, Starting S  
Indications: Coronary/Peripheral Artery Disease

rivaroxaban (XARELTO)  
 rivaroxaban (XARELTO) tablet 2.5 mg, oral, 2 times daily at 0900, 1700  
Indications: Coronary/Peripheral Artery Disease

( ) Prophylaxis of DVT following hip or knee surgery

Pharmacy consult to monitor rivaroxaban (XARELTO) therapy STAT, Until discontinued, Starting S  
Indications: VTE prophylaxis

rivaroxaban (XARELTO) (Single Response)  
Avoid use in patients with CrCl LESS than 30 mL/min

( ) Hip 10 mg, oral, daily  
Indications: VTE prophylaxis

( ) Knee 10 mg, oral, daily  
Indications: VTE prophylaxis

( ) Other indication

Pharmacy consult to monitor rivaroxaban (XARELTO) therapy      STAT, Until discontinued, Starting S  
Indications: Other: Specify  
Specify Other Indication:

rivaroxaban (XARELTO)

rivaroxaban (XARELTO) tablet      oral  
Indications: Other: Specify  
Specify Other Indication:

## Labs

### Baseline labs

Per HM policy, baseline labs are required prior to initiation of therapy if not already available.

CBC with platelet and differential      Once For 1 Occurrences

Prothrombin time with INR      Once For 1 Occurrences

Partial thromboplastin time, activated      Once For 1 Occurrences

Basic metabolic panel      Once For 1 Occurrences

### Follow-up Labs

CBC with platelet and differential      AM draw repeats For 3 Occurrences

Creatinine level      AM draw repeats For 3 Occurrences

Anti Xa Rivaroxaban      AM draw For 1 Occurrences

CBC with platelet and differential      User Schedule, Starting S+1 For 3 Occurrences

Creatinine level      User Schedule, Starting S+1 For 3 Occurrences

Anti Xa Rivaroxaban      Once

## Consults